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Abstract
Background—Differences in the breast cancer burden of African American compared with
White American women are well-documented. Recent controversies have emerged regarding age-
appropriate mammographic screening guidelines, and these surveillance recommendations may
influence future breast cancer disparities. Our goal was to evaluate age-specific breast cancer stage
distributions and incidence rates of triple-negative breast cancer (TNBC) in a population-based
tumor registry.
Study Design—We analyzed California Cancer Registry (CCR) breast cancers diagnosed 1988
– 2006. Results were stratified by age and race/ethnicity, with White Americans identified as Non-
Hispanic Whites (NHW) and African Americans as Non-Hispanic Blacks (NHB). Breast cancer
stage distributions and TNBC incidence rates were also analyzed.
Results—A total of 375,761 invasive breast cancers were evaluated (including 276,938 in NHW
and 21,681 in NHB) NHB and Hispanics tended to be younger than NHW (median ages 57; 54;
and 64 years, respectively). Lifetime incidence rates were higher for NHW compared to NHB and
Hispanics, but for women younger than 44 years incidence was highest among NHB. NHB also
had higher incidence rates of Stage III and IV disease, and higher incidence of TNBC in all age
categories.
Conclusions—Population-based data demonstrate that African American women have a more
advanced stage distribution for breast cancer compared to White Americans, and higher incidence
rates for TNBC. These patterns are observed for women age 40–49 years as well as older women,
and suggest that mammographic screening for early detection of breast cancer will be particularly
relevant for younger African American women.
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More than 200,000 women are diagnosed with breast cancer each year in the United States
and approximately 40,000 are projected to die with this disease annually(1). Breast cancer
mortality rates have declined over the past twenty years in the United States, and this
improvement in outcome is largely explained by the combination of earlier detection with
screening mammography coupled with utilization of more effective systemic therapy(2).
Systemic therapy options for breast cancer are determined by the molecular marker
expression of individual tumors. The best outcomes are therefore observed for cancers that
are either detected early (i.e. when the distant organ micrometastatic risk is low) or that have
a marker pattern indicating high likelihood of controlling micrometastases with targeted
treatment such as endocrine therapy for hormone receptor-positivity and/or trastuzamab for
HER2/neu overexpression. Conversely, tumors that are detected at advanced stages or that
are negative for these markers are more likely to be associated with breast cancer mortality.
Population-based data regarding the breast cancer burden of different subsets of the
American female population have revealed several interesting albeit incompletely-
understood patterns. Most notably, African American women have a lower lifetime risk of
breast cancer, but mortality rates are paradoxically higher when compared to White
American women(3). The age-incidence curves also differ; among women younger than age
45 years the incidence rates are higher for African Americans compared to White
Americans. Furthermore, frequency of breast tumors that are negative for the estrogen
receptor (ER); the progesterone receptor (PR); and/or the HER2/neu marker is also
increased among African American women(4).
Breast cancer screening with annual mammography beginning at age 40 years has been
advocated since the mid-1990’s by organizations such as the American Cancer Society; the
American College of Surgeons; and the National Comprehensive Cancer Network. This
recommendation was challenged recently by the U.S. Preventive Services Task Force
(USPSTF) which issued a published statement in November 2009 in support of deferring
initiation of mammography screening until age 50 years(5). Presumably, this screening
strategy could have a disproportionately adverse effect on women facing an increased risk of
being diagnosed with early-onset breast cancer, advanced-stage disease, and/or biologically-
more aggressive tumors. The goal of this project was to assess the potential implications of
the USPSTF recommendation relative to African American women, by computing age-
specific, population-based stage distributions for breast cancer as well as age-specific
incidence rates of TNBC. For these analyses we relied upon data from the population-based
California Cancer Registry (CCR). The CCR has provided valuable information regarding
disparities in breast cancer related to racial/ethnic identity since 1988 (6–9).
Methods
An analysis of the California Cancer Registry (CCR) data from 1988 to 2006 was
performed. Age-adjusted and age-specific invasive breast cancer incidence rates for the
three major race/ethnic groups (Non-Hispanic White [NHW]; Non-Hispanic Black [NHB];
and Hispanic) were computed using data from the CCR. The CCR is a population-based
cancer registry which has monitored cancer incidence and mortality in California since
1988. SEER*Stat 6.5.2 program was used to analyze the CCR database, including 95%
confidence intervals(10). Statistical significance testing was based upon chi-squared
comparisons for categorical variables and based upon student’s t-test to compare the mean
values of continuous variables. P-values of less than 0.05 were considered statistically
significant.
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The CCR database for breast cancer was analyzed by American Joint Committee on Cancer
(AJCC) seventh edition stage at diagnosis, stratified by age (categorized as <40 years, 40 to
49 years, 50 to 59 years, 60 to 74 years, and >=75 years) and then comparisons were
evaluated with respect to the racial/ethnic subsets of the California population. Racial/ethnic
identity was assigned by self-report as documented by the tumor registries contributing to
the CCR program.
Staging information and positive versus negative hormone receptor status (estrogen receptor,
progesterone receptor) was also assigned according to the information contributed by the
CCR registrars. For HER2/neu expression, positive or negative status was based upon
documented immunohistochemistry and/or FISH staining. Statistics for TNBC incidence
rates were limited to cases diagnosed beginning 2004. Documentation of HER2/neu status
was felt to be more uniform and complete during this latter interval, when clinical trial
results regarding effectiveness of adjuvant trastuzamab for HER2/neu-overexpressing breast
cancer were more widely-available and this component of molecular marker information
therefore became more relevant on a routine basis for all women diagnosed with invasive
breast cancer (11, 12).
Results
A total of 375,761 women were newly-diagnosed with invasive breast cancer as reported in
the California Cancer Registry from 1988 – 2006. Of these, NHW accounted for 278,241
(74%); NHB accounted for 21,716 (5.8%); and Hispanics 45,523 (12.1%).
The median age at diagnosis was 64, 57, and 54 years for the NHW, NHB, and Hispanic
patients, respectively. The median age at diagnosis for patients with unknown racial/ethnic
background was 61.5 years. As demonstrated by the age-incidence rates shown in Table 1
and the age-incidence curves depicted in Figure 1, the risk of breast cancer rises with
increasing age for all of the racial/ethnic subsets evaluated. Figure 1 also shows that among
women younger than age 44 years, population-based incidence rates of breast cancer are
highest for NHB; for women older than 44 years, incidence rates are highest for NHW.
Incidence rates are lowest for Hispanic women in all age categories. Incidence rates of
Stages 1 and 2 breast cancer were lower for NHB compared with NHW in all age categories,
but incidence rates for Stages 3 and 4 disease were higher for NHB. Breast cancer incidence
rates by any stage were generally lower for Hispanics compared with NHW in all age
categories.
Figure 2 shows the incidence rates by stage for the study population subsets, and
demonstrates the shift toward more frequent detection of advanced-stage disease (stages III
and IV) for NHB compared to NHW and Hispanics.
As shown in Figure 3, most of the rising breast cancer incidence rates associated with
increasing age is a consequence of increasing risk for non-triple negative breast cancer
(TNBC). Incidence rates for TNBC are less than 50 cases per 100,000 population (all race-
ethnic groups combined) in all age categories, but these rates slowly rise with age and
plateau beyond the fifth decade of life.
Table 2 and Figure 4 demonstrate the increased risk of TNBC for NHB women in all age
categories. Incidence of TNBC rise more steeply with increasing age for NHB compared to
NHW and Hispanics, with these incidence rates approximately twofold higher for NHB
compared to either of the other subsets in the 40–49 and 50–59 year-old age categories. The
TNBC incidence rates peak at 64.4 per 100,000 NHB in the 60–74 year-old age category.
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Recent challenges to the traditional recommendations that American women initiate annual
screening mammography at age 40 years have the potential for exerting a disproportionately
adverse effect on African American women because of the well-documented younger age
distribution for breast cancer in this population subset. Early detection of breast cancer is the
most powerful determinant of outcome, and this will be particularly relevant for tumors
expressing phenotypes that cannot be controlled with targeted agents such as endocrine
therapy and/or trastuzamab. African American women have higher mortality rates from
breast cancer, and this is at least partially explained by the fact that they tend to present with
more advanced stages compared to White American women. They therefore represent a
community that has been the focus of many breast cancer awareness and screening/early
detection programs. Our study provides further evidence of the need to continue intensive
breast cancer surveillance among African American women age 40–49 years. By studying
data from the California Cancer Registry, we found higher population-based incidence rates
of locally-advanced breast cancer and triple-negative breast cancer among African American
women.
Although the lifetime incidence rates of breast cancer are higher for White American
compared to African American women, the Surveillance, Epidemiology and End Results
(SEER) Program documents that for women younger than age 45 years, population-based
incidence rates are higher for African Americans(13). Several investigators have
demonstrated that the frequency of TNBC is higher for African American compared to
White American breast cancer patients (14–17). Carey et al (18) furthermore demonstrated
that the risk of triple-negative breast cancer is particularly high among premenopausal
African American women, based upon analysis of the Carolina Breast Cancer Study. By
reporting on age- and race/ethnicity- specific patterns of disease in the California Cancer
Registry, our study provides powerful population-based evidence regarding the importance
of aggressive screening for early detection of breast cancer in young African American
women.
As background for the updated screening guidelines presented by the U.S. Preventive
Services Task Force (USPSTF) in November 2009(5) reviews of the data from the historic
mammography screening trials were prepared by Nelson et al(19) and Mandelblatt et al on
behalf of the Cancer Intervention and Surveillance Modeling Network (CISNET)(20). In
summary, they found that for women age 40–49 years, approximately 1900 must be invited
to mammographic screening in order to save one life; for women age 50–59 years,
approximately 1300 must be invited; and for women age 60–69 years, approximately 400
must be invited. They also found that initiation of mammography screening at age 40 rather
than age 50 years results in an average gain of 33 life years per 1000 women screened.
CISNET therefore stated: “If the goal of a national screening program is to reduce mortality
in the most efficient manner, then programs that screen biennially from age 50 years…are
among the most efficient on the basis of the ratio of benefits to the number of screening
mammograms. If the goal of a screening program is to efficiently maximize the number of
life-years gained, then the preferred strategy would be to screen biennially starting at age 40
years.”(20) The USPSTF opted to advocate in favor of supporting an efficiency-based
screening model rather than a longevity-based program, and they therefore issued the
statement that “The USPSTF recommends against routine screening mammography in
women aged 40–49 years… The USPSTF recommends biennial screening mammography
for women between the ages of 50 and 74 years.”(5) CISNET furthermore commented that
none of the mammography screening models were likely to capture differences in outcome
among specific population subsets such as “black women who seem to have more disease at
younger ages than white women”(20). The USPSTF recommendation statement did not
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comment on the potential impact of their screening recommendations on race-ethnicity-
associated breast cancer disparities.
Our study serves to inform the discussion regarding relevance of mammography screening
for African American women age 40–49 years. We found more advanced stage of disease at
diagnosis in these younger African American women, and we also found higher incidence
rates of TNBC for this population subset. Since mammography screening programs should
improve early detection rates for breast cancer, and since early detection of TNBC is critical
for improving its successful treatment, we believe that our study findings provide
compelling evidence that screening mammography should be particularly important for
young African American women. The USPSTF recommendation that routine screening
mammography should not be initiated until age 50 years has the potential for widening the
magnitude of breast cancer outcome disparities between African American and White
American women.
The CCR data on race/ethnicity-associated frequency of TNBC is consistent with other
studies, as shown in Table 3. The population-based incidence rates featured in our study
serve to strengthen the validity of these observations. These rates indicate an inherently
higher risk of TNBC for NHB/African American women, refuting the argument that the
larger proportion of TNBC in African American women is an artifact of the “denominator”
phenomenon (i.e. African American women appear to have more TNBC simply because
they have fewer total breast cancers compared to White American women). Our data on
women from California demonstrate increased population-based risk of TNBC for NHB
women.
Our study is limited by our unfortunate inability to correlate mammography screening
information with the age- and race/ethnicity-specific breast cancer incidence rates. However
data from the California Health Interview Survey (CHIS) indicate similar mammography
utilization rates for African American and White American women, but somewhat lower
rates for Hispanic/Latina women (unpublished data) and this finding mirrors national data
on mammography utilization reported by the American Cancer Society(1). Although the
data regarding effectiveness of mammography in detecting TNBC (compared to detection
rates for non-TNBC) are limited, the available published studies indicate that frequency of
mammographically-occult breast tumors is similar for TNBC and non-TNBC. TNBC does
however, appear to be less-frequently associated with microcalcifications and is more likely
to be identified as a mass or asymmetric density(21–24). Furthermore, Ma et al
demonstrated that mammographic density (a common imaging finding among
premenopausal women) is a risk factor for TNBC as well as for non-TNBC(25).
Another notable limitation of our study is the fact that the CCR (similar to the SEER
Program) lacks detailed information on menstrual history and reproductive factors. Millikan
et al(26) and other investigators(27) have suggested that childbearing patterns and lactation
history may account for race/ethnicity-associated variation in breast cancer burden. Others
have been unable to confirm these hypotheses (28). Yet other investigators have reported
elevated risk of TNBC among contemporary female populations of continental Africa(29–
31), suggesting that African ancestry may be associated with some heritable risk factor for
TNBC(32). Our population-based California dataset is unable to address any of these issues.
In summary, our data from California (which appears to be representative of national data)
demonstrates increased risk of advanced-stage breast cancer and triple-negative breast
cancer in African American women compared to White American and Hispanic American
women. These patterns are notably prominent for women younger than age fifty, suggesting
that mammography screening to improve early detection of biologically-aggressive patterns
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of breast cancer will be particularly relevant for younger African American women,
especially since overall breast cancer incidence rates are higher for African American
women in the premenopausal age range.
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Age-specific breast cancer incidence rates in women under 50 years at age of diagnosis by
Race/Ethnicity for California Cancer Registry. Note: Crossover in age-incidence curves
between NH Whites and NH Blacks occurs in 40–44 year interval (arrow), with higher
incidence rates among younger NH Blacks. NH = Non-Hispanic
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Age adjusted incidence rates of female breast cancer by race/ethnicity and stage at diagnosis
from the California Cancer Registry. NH = Non-Hispanic
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Triple Negative Breast cancer (TNBC) compared with all other breast cancers (BC);
Incidence rates per 100,000 by age from the California Cancer Registry.
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California Cancer Registry, Triple Negative Breast Cancer incidence rates by age and race
[rates are per 100,000 and age-adjusted to the 2000 US Std Population (19 age groups -
Census P25-1130) standard; Confidence intervals (Tiwari mod) are 95% for rates]. NH =
Non-Hispanic
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